A Phase I Single Center Study of Ranibizumab in Combination With Proton Beam Irradiation for Choroidal Melanoma
Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment
incidence and severity of ocular adverse events and systemic adverse events
12 months and 24 months after initial treatment
Ivana Kim, M.D.
Massachusetts Eye and Ear Infirmary
United States: Food and Drug Administration
|Massachusetts Eye & Ear Infirmary||Boston, Massachusetts 02114|